Skip to Main Content

Paper Details

High-Sensitivity C-Reactive Protein is a Prognostic Biomarker of Six-Month Disability after Traumatic Brain Injury: Results from the TRACK-TBI Study.
J Neurotrauma
32
2021
C-Reactive Protein, C-reactive protein, CRP, GFAP, High-sensitivity CRP, OTC, OTCs, Serum hsCRP, TBI, Traumatic Brain Injury, glial fibrillary acidic protein, hsCRP, orthopedic injury, participants, patients, traumatic brain injury
Author NameAffiliation
John K YueUniversity of California San Francisco
John K YueZuckerberg San Francisco General Hospital
Frederick K KorleyUniversity of Michigan ann arbor
Ava M PuccioUniversity of Pittsburgh Medical Center
Esther L YuhUniversity of California San Francisco
Esther L YuhZuckerberg San Francisco General Hospital
Xiaoying SunUniversity of California San Diego
Mary J VassarUniversity of California San Francisco
Mary J VassarZuckerberg San Francisco General Hospital
Sabrina R TaylorUniversity of California San Francisco
Sabrina R TaylorZuckerberg San Francisco General Hospital
Michael McCreaMedical College of Wisconsin
Murray B SteinUniversity of California San Diego
Claudia S RobertsonBaylor College of Medicine
Harvey S LevinBaylor College of Medicine
Sureyya DikmenUniversity of Washington
Nancy TemkinUniversity of Washington
Joseph T GiacinoSpaulding Rehabilitation Hospital, Harvard Medical School
Pratik MukherjeeUniversity of California San Francisco
Pratik MukherjeeZuckerberg San Francisco General Hospital
Kevin K W WangMcKnight Brain Institute, University of Florida
David O OkonkwoUniversity of Pittsburgh Medical Center
Amy J MarkowitzZuckerberg San Francisco General Hospital
Sonia JainUniversity of California San Diego
Geoffrey T ManleyUniversity of California San Francisco
Geoffrey T ManleyZuckerberg San Francisco General Hospital
Geoffrey T ManleyUniversity of California San Francisco
Geoffrey T ManleyZuckerberg San Francisco General Hospital
Ramon Diaz-ArrastiaUniversity of Pennsylvania
  • 1 - 29

Datasets

Release 1.2